Mark Gergen, Poseida CEO
August 3, 2022 07:30 AM EDTUpdated 10:38 AM
Deals
Cell/Gene Tx

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Roche has tak­en its next big step in­to the al­lo­gene­ic CAR-T field, this time ty­ing up along­side Po­sei­da Ther­a­peu­tics $PSTX with $220 mil­lion in up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times